Last reviewed · How we verify

Instituto Fernandes Figueira — Portfolio Competitive Intelligence Brief

Instituto Fernandes Figueira pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Nicotine replacement Nicotine replacement marketed Nicotinic acetylcholine receptor agonist Nicotinic acetylcholine receptors Smoking Cessation / Addiction Medicine

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. 22nd Century Group, Inc. · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. GlaxoSmithKline · 1 shared drug class
  4. Iowa City Veterans Affairs Medical Center · 1 shared drug class
  5. Johns Hopkins University · 1 shared drug class
  6. Medical University of Vienna · 1 shared drug class
  7. Ottawa Hospital Research Institute · 1 shared drug class
  8. University of Auckland, New Zealand · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Instituto Fernandes Figueira:

Cite this brief

Drug Landscape (2026). Instituto Fernandes Figueira — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/instituto-fernandes-figueira. Accessed 2026-05-16.

Related